Full Press Release Details
Melanie Nimrodi, Media Contact
Robert McNally / Jennifer Nelms
GeoVax Appoints Mr. Peter M Tsolinas to its Board of Directors
ATLANTA, GA, August 20, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based
biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human
Immunodeficiency Virus) and other infectious agents, is pleased to announce the addition of Peter
M. Tsolinas as a member of its Board of Directors. Tsolinas, having supported the Company through
private investments, now joins the Company s Board to further his contribution through his talent
and three decades of business and banking experience.
Mr. Tsolinas currently serves as Chairman and CEO of TMA Group Development Corp., a Chicago based
real estate, architectural and development firm. As a real estate developer over the last 30
years, Tsolinas has built a successful network of companies involved in architectural, development
and construction of commercial, industrial and institutional facilities. During that time,
Tsolinas has participated in joint ventures and partnerships with Lincoln National Life,
Commonwealth Edison, and ADP Corporation, as well as individual private investors. Further, Mr.
Tsolinas has achieved additional successes through his personal investments in the real estate and
banking sector, where he served on several bank boards from 1977 through 2006.
As a substantial investor in GeoVax, I am honored to join its Board of Directors to further assist
the Company directly, said Tsolinas. I have been truly intrigued by Dr. Harriet Robinson s
scientific efforts and dedication to help humanity and I look forward to continue supporting her
and the Company in their quest to cure the HIV/AIDS pandemic.
Tsolinas continued, With the exceptional trial data the Company has demonstrated to date, I
envision a very promising future for GeoVax and its shareholders. I am personally humbled to be an
integral part of its success going forward.
Robert McNally, GeoVax s President and Chief Executive Officer, commented, We are very pleased
that Mr. Peter Tsolinas has agreed to join our Board of Directors. His substantial business
experience will enhance and complement that of our current Board members. Peter has been a
faithful supporter of GeoVax and we welcome his further contributions to our success through
service on our Board.
Mr. Tsolinas earned a B.A. degree in Architecture with a minor in Byzantine History from the
University of Illinois. He has been a speaker and panelist at numerous Architectural and
Development Conferences and is a member of the Chicago and National Chapter of The American
Institute of Architects, as well as a corporate member of NCARB and NAIOP. He has been engaged in
several philanthropic projects and currently serves as Chairman of the Stewardship Committee at St.
Nectarios Greek Orthodox Church.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other
infectious agents. GeoVax s AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired
Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become
infected. GeoVax AIDS vaccines also may be effective as therapeutics, treatment of people already
infected with AIDS virus.
GeoVax s core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of
Research and Development, through a collaboration of colleagues at Emory University s Vaccine
Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention
GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine
Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative
agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials
program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant
awarded in late 2007.
Safe Harbor Statement: All statements in this news release, which are not statements of historical
fact, are forward-looking statements. These statements are based on expectations and assumptions on
the date of this press release and are subject to numerous risks and uncertainties which could
cause actual results to differ materially from those described in the forward-looking statements.
Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and
manufacture these vaccines with the desired characteristics in a timely manner, GeoVax s vaccines
will be safe for human use, GeoVax s vaccines will effectively prevent AIDS in humans, vaccines
will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required
capital to complete vaccine development, there is development of competitive products that may be
more effective or easier to use than GeoVax s products, and other factors over which GeoVax has no
control. GeoVax assumes no obligation to update these forward-looking statements, and does not
intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the
Company s Securities and Exchange Commission filings and reports.